2024-517535-52-00招募中4 期
Single center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of neoadjuvant and adjuvant Pembrolizumab on top of standard Chemo-Radiotherapy (Stupp protocol) in Treatment of Patients with newly diagnosed Glioblastoma Multiforme (GBM). (PIRG)
Medical University Of Silesia Katowice Poland2 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2024年11月5日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
- 试验地点
- 2
- 主要终点
- Safety and tolerability – incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) related and unrelated with Pembrolizumab
研究概览
简要总结
To evaluate the short-term and longer-term safety, tolerability, and effectiveness of neoadjuvant and adjuvant Pembrolizumab on top of standard therapy (Stupp protocol) in patients with Glioblastoma Multiforme (GBM).
研究设计
- 分配方式
- Randomized
- 主要目的
- Follow-up
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Signed Informed Consent Form
- •For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use double barrier contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 120 days after the last immuno-PET imaging.
- •For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use double barrier contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 120 days after the last immuno-PET imaging.
- •Age ≥ 18 years
- •Age ≤70 years
- •Able to comply with the study protocol in the investigator’s judgment
- •Clinically and radiologically (contrast CT, full profile MRI – T1-weighted with or without contrast, T2-weighted, FLAIR, DWI, PWI, MR-spectroscopy) confirmed diagnosis of GBM, localized outside eloquent brain areas
- •Resectable tumor
- •Fully physically active ≥80 points in Karnofsky performance scale
- •Life expectancy of at least 3 months
- •Adequate organ function (confirmed within 1 weeks before enrollment):a) Hemoglobin ≥ 9g/dL , b) Absolute Neutrophils Count (ANC) ≥1.5×10^9/L, c) White Blood Cells (WBC) count ≥3×10^9/L, d) Platelets (PTL) ≥ 100×10^9/L, e) AST/ALT ≤2.5×ULN, f) Serum creatinine (S-Cr) ≤ ULN, g) Glomerular Filtration Rate (GFR) ≥50mL/min, h) Albumin ≥ LLN , i) Bilirubin ≤ 1.5 ULN (except patients with documented Gilbert’s Syndrome, who must present adequate level of direct bilirubin),j) International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5×ULN. (Elevation of INR and aPTT due to administration of anticoagulation drugs is not a contraindication for the enrollment. However, it must return to normal range prior to surgery).
排除标准
- •Any active concomitant malignancy, except: a. Locally treated basal or squamous cell carcinoma b. Cervical carcinoma in situ c. Breast cancer in situ d. Bladder cancer in situ e. Low grade prostate cancer (under observation with PSA level in normal range)
- •History of tuberculosis
- •Any mental disorder that may affect patient's participation
- •Any drug or psychoactive substance dependence
- •Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol
- •Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to study treatment initiation
- •Major surgical procedure within 4 weeks prior to study enrollment or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis
- •Any live vaccination within 30 days before enrollment
- •Any active immunosuppressive systemic infection including history of human immunodeficiency virus (HIV) infection
- •Body mass index (BMI) ≥ 35 kg/m2
- •Pregnant or lactating or intending to become pregnant during the study – women who are not postmenopausal (postmenopausal defined as ≥ 12 months of non-drug-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 2 weeks prior to initiation of study treatment
- •Any previous systemic cancer treatment, including, but not limited to: a. Radiotherapy b. Brachytherapy for brain tumor c. Chemotherapy d. Carmustine wafer treatment (Gliadel®) e. Any immune checkpoint inhibitor therapy or any anticancer vaccination
- •Any condition that the patient's physician determines to be detrimental to the patient participating in this study; including any clinically important deviations from normal clinical laboratory values or concurrent medical events
- •Inability to understand the local language for use of the patient QoL instruments
- •Tumor other than glioblastoma grade 4 IDH-wildtype, astrocytoma grade 3 or 4 IDH-mutant identified in post-surgery histopathology.
- •Presence of 1p19q codeletion
- •Hypersensitivity or allergy to any substance with similar action mechanism to Pembrolizumab, Atezolizumab, Temozolomide, other monoclonal antibodies or contrast agents
- •Any active immunosuppressive systemic therapy (except corticosteroids less or equal to 12mg of dexamethasone equivalent; the dose of dexamethasone should be kept as low as possible throughout the whole duration of this trial)
- •Any active autoimmune disease or systemic therapy for autoimmune disease within 2 years before enrollment
- •History of any immunodeficiency
- •Active infection
- •Significant cardiovascular disease, such as New York Heart Association cardiac disease ≥ Class III, myocardial infarction within 3 months, coronary artery disease, unstable arrhythmias or unstable angina
- •Active liver disease, hepatitis, HBV or HCV infection
结局指标
主要结局
Safety and tolerability – incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) related and unrelated with Pembrolizumab
Safety and tolerability – incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) related and unrelated with Pembrolizumab
Patient-Reported Outcomes to evaluate health status and Quality of Life (QoL) instruments for patients with GBM: Eastern Cooperative Oncology Group (ECOG) status - Karnofsky Performance Status (KPS), - EORTC: QLQ-BN20 (brain), and QLQ-C30 (general cancer questionnaire).
Patient-Reported Outcomes to evaluate health status and Quality of Life (QoL) instruments for patients with GBM: Eastern Cooperative Oncology Group (ECOG) status - Karnofsky Performance Status (KPS), - EORTC: QLQ-BN20 (brain), and QLQ-C30 (general cancer questionnaire).
次要结局
未报告次要终点
研究者
Clinical trial information desk
Scientific
Medical University Of Silesia Katowice Poland
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Neoadjuvant Lu-PSMA radioligand therapy and Ipilimumab in men with very high-risk prostate cancer (NEPI)2024-514386-19-00Universitaetsklinikum Essen AöR58
招募中
2 期
A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk of relapse2023-505223-31-00European Organisation For Research And Treatment Of Cancer347
招募中
不适用
Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal CancerNCT07269249National Cancer Institute, Naples50
招募中
2 期
SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARCNCT07284992Shandong Provincial Hospital208
招募中
2 期
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)NCT07283692RenJi Hospital46